Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

RIEPILOGO 2 sugli effetti comportamentali della psilocibina

3 novembre 2026 aggiornato da: University of Wisconsin, Madison

Ruolo dell'esperienza, della consapevolezza cosciente e della plasticità negli effetti comportamentali della psilocibina - Studio di follow-up (studio RECAP 2)

The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.

Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing.

Participants will:

  • Receive one of four possible combinations of medications
  • Undergo an MRI
  • Complete questionnaires
  • Undergo transcranial magnetic stimulation (TMS) and EEG
  • Volunteer for an open-label follow-up phase of study

Panoramica dello studio

Descrizione dettagliata

The purpose of this study is to investigate the role that inducing neuroplasticity plays in the behavioral effects of psilocybin in people with modest decrements in emotional wellbeing.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Wisconsin
      • Madison, Wisconsin, Stati Uniti, 53792
        • Reclutamento
        • UW School of Medicine and Public Health

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age 18 to 65 years at screening, of any identified gender and racial/ethnic group
  • Physically healthy; does not meet criteria for an exclusionary medical condition
  • English-speaking (able to provide consent and complete questionnaires)
  • Modest decrement in self-reported wellbeing without the presence of a DSM-5 Axis I mood or anxiety disorder
  • Able to undergo magnetic resonance imaging (MRI) and transcranial magnetic stimulation (TMS)

Exclusion Criteria:

  • Exclusionary DSM-5 psychiatric diagnosis and/or active suicidal ideation
  • Exclusionary medical conditions
  • Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)
  • Clinically significant electrocardiogram (ECG)
  • Use of psychotropic or CNS-altering medications within 3 months of screening
  • Hypertension or tachycardia

Participants invited to participate in the 28-day open label follow-up phase will:

  1. Fully complete all activities associated with the randomized phase, including the virtual Day 84 assessment, before being approached about participation in the open label phase.

  2. Participants who meet stopping criteria during the randomized phase are not eligible to enroll in the open label phase.

  3. Participants who withdraw from the randomized phase are not eligible to enroll in the open label phase.

  4. Enrollment into the open label phase must occur in the following sequence:

    1. participants who have fully completed the randomized phase are screened for eligibility;
    2. eligible participants meet with the study team and provide informed consent for the open label phase;
    3. baseline eligibility is reassessed to confirm that participation in the open label phase remains appropriate and safe.

The Principal Investigator may decline or defer open-label enrollment when unresolved concerns make participation unsafe or scientifically inappropriate.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Group 1: Psilocybin and intravenous (IV) midazolam

Psilocybin (25 mg) + IV midazolam

25mg of psilocybin

Altri nomi:
  • Psilocibina

1mg of psilocybin

Altri nomi:
  • Psilocibina

The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.

Sperimentale: Group 2: Psilocybin and IV saline

Psilocybin (25 mg) + IV saline (placebo for midazolam)

25mg of psilocybin

Altri nomi:
  • Psilocibina

1mg of psilocybin

Altri nomi:
  • Psilocibina

Saline will be administered as a placebo for midazolam

Sperimentale: Group 3: Psilocybin and IV midazolam

Psilocybin (1 mg/control) + IV midazolam

25mg of psilocybin

Altri nomi:
  • Psilocibina

1mg of psilocybin

Altri nomi:
  • Psilocibina

The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.

Sperimentale: Group 4: Psilocybin and IV saline

Psilocybin (1 mg/control) + IV saline

25mg of psilocybin

Altri nomi:
  • Psilocibina

1mg of psilocybin

Altri nomi:
  • Psilocibina

Saline will be administered as a placebo for midazolam

Sperimentale: Exploratory Open Label Follow-Up Phase

Psilocybin (25 mg)

25mg of psilocybin

Altri nomi:
  • Psilocibina

1mg of psilocybin

Altri nomi:
  • Psilocibina

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Warwick-Edinburgh Mental wellbeing Scale (WEMWBS)
Lasso di tempo: Baseline to 7 days post-dose

WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing.

Baseline to 7 days post-dose
Change in Brief Experiential Avoidance Questionnaire (BEAQ)
Lasso di tempo: Baseline to 7 days post-dose

The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance

Baseline to 7 days post-dose
Change in Probabilistic Reversal Learning (PRL)
Lasso di tempo: Baseline to 7 days post-dose

Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift).

Baseline to 7 days post-dose
Change in transcranial magnetic stimulation evoked potential (TEP) amplitude
Lasso di tempo: Baseline to 7 days post-dose

TEP measures neural excitability in the stimulated region of the brain.

Baseline to 7 days post-dose

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in WEMWBS
Lasso di tempo: Baseline to 28 days post-dose

WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing.

Baseline to 28 days post-dose
Change in BEAQ
Lasso di tempo: Baseline to 28 days post-dose

The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance

Baseline to 28 days post-dose
Change in PRL
Lasso di tempo: Baseline to 28 days post-dose

Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift).

Baseline to 28 days post-dose
Change in TEP amplitude
Lasso di tempo: Baseline to 28 days post-dose

TEP measures neural excitability in the stimulated region of the brain.

Baseline to 28 days post-dose
Altered States of Consciousness (ASC) questionnaire
Lasso di tempo: Dosing 1 day

Participants will complete a selection of several questions from the ASC questionnaire that strongly associate positively or negatively with later antidepressant effect of psilocybin in patients with treatment resistant depression or capture classic features of the psychedelic experience. During the dosing session, investigator will repeatedly ask selected items from the ASC scale to get a "real time" measure of what the participants are experiencing. Each of these items will be scored separately. Higher score are indicative of a more intense psychedelic experience.

Dosing 1 day
Emotional Breakthrough Inventory (EBI)
Lasso di tempo: Dosing 1 day

The EBI is a 6-item scale that assesses the presence and severity of emotionally challenging/distressing experiences that occur during a psychedelic experience. Participants rate to what extent the statements apply to their experience by marking a single line across each scale. Scale ranges from not at all to very much so. Higher scores (more slashes toward the 'very much so' end) on the scale have been associated with enhanced well-being following psychedelic use

Dosing 1 day
Psychological Insight Questionnaire (PIQ)
Lasso di tempo: Dosing 1 day

The PIQ is a 23-item instrument designed to query self-perceived attainment of insight during a psychedelic medicine session. Items are rated on a 6-point Likert scale, 0 = no not at all and 5 = extremely. Possible scares range from 0-115, with higher scores indicating greater insight.

Dosing 1 day

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Charles Raison, MD, University of Wisconsin, Madison

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 agosto 2025

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 dicembre 2027

Date di iscrizione allo studio

Primo inviato

14 novembre 2024

Primo inviato che soddisfa i criteri di controllo qualità

15 novembre 2024

Primo Inserito (Effettivo)

18 novembre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • 2024-0852
  • A538900 (Altro identificatore: UW- Madison)
  • SMPH/PSYCHIATRY/PSYCHIATRY (Altro identificatore: UW- Madison)
  • Protocol Version 9/30/2026 (Altro identificatore: UW- Madison)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi